Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer
| Autor: | Ahmed Gaber Abdelraheem, Ashraf Elyamany, Elsayed Mostafa Ali, Emad Eldin Nabil, Ahmed M. Maklad |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cisplatin
Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Head and neck cancer medicine.disease Gemcitabine law.invention Radiation therapy Randomized controlled trial law Internal medicine Medicine Stage (cooking) business Chemoradiotherapy medicine.drug |
| Zdroj: | Journal of Cancer Treatment and Research. 2:37 |
| ISSN: | 2376-7782 |
| Popis: | PURPOSE: In our study we compared low-dose gemcitabine-based chemoradiotherapy with cisplatin-based chemoradiotherapy as regards response rate, survival and toxicity profile in locally advanced head and neck cancer. Methodology: sixty patients with locally advanced head and neck cancer were included in this prospective comparative randomized study, in the period from January 2011 to September 2013. Results: The patients were treated in two randomized groups; each of them included 30 patients. In gemcitabine arm (group A), 42.3% of the patients had stage III, and 57.7% of them had stage IVa while 48.15% of the patients of cisplatin arm (group B) had stage III and 51.85% had stage IVa. The median duration of response in group A was 21 months, while in group B it was 23 months. The degree of response had a statistically significant effect on survival in group B patients. It was evident in patients who achieved partial response (PR) that showed lower survival than those with (CR). Conclusion: Gemcitabine has comparable radiosensitizing effect with acceptable toxicity profile and can be used as a radiosensitizer in head and neck cancers especially when cisplatin cannot be used. We recommend further studies to establish its rule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|